Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus placebo in relapsed mesothelioma
ISRCTN79814141Phase 3Completed
- Sponsor
- University of Southampton
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of nivolumab in mesothelioma, sponsored by University of Southampton. Primary endpoint: Overall survival. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
mesothelioma
Beyond the preview
Go deeper on ISRCTN79814141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN79814141.